(RTTNews) - Viracta Therapeutics, Inc. (VIRX) Wednesday reported positive results from Phase 2 NAVAL-1 study of nanatinostat in combination with antiviral agent valganciclovir (Nana-val) in patients with relapsed/refractory Epstein-Barr virus (EBV)-positive peripheral T-cell lymphoma (PTCL).
A total of 21 patients with primarily stage III-IV disease received nanatinostat in combination with valganciclovir across the first two stages of the study. Combined Stage 1 and Stage 2 results from the Phase 2 NAVAL-1 trial showed overall response rate of 33 percent and the complete response rate of 19 percent.
Further, Nana-val was generally well-tolerated.
"Published literature suggests that EBV-positive lymphomas are a distinct oncological disease associated with poorer survival outcomes than EBV-negative lymphomas. We believe it is critical to treat these patients as early as possible with an EBV-targeted therapy to improve patient outcomes. Our updated Nana-val clinical development plan is designed to address this urgent need and expedite a randomized controlled trial, which we plan to initiate in 2025 to support potential registration," said Mark Rothera, President and Chief Executive Officer of Viracta.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
